Congenital Hyperinsulinism - Notes for the General Pediatrician

Area of Science:

• Pediatrics
• Endocrinology
• Genetics

Background:

• Congenital hyperinsulinism (CHI) is a rare but significant cause of persistent hypoglycemia in neonates.
• Hypoglycemia can lead to neuroglycopenia and lifelong neurodisability if not promptly managed.
• Identifying CHI in newborns with recurrent hypoglycemia and high glucose needs is critical.

Purpose of the Study:

• To emphasize the importance of early recognition and management of congenital hyperinsulinism.
• To outline diagnostic biochemical and genetic approaches.
• To discuss therapeutic strategies including medical and surgical options.

Main Methods:

• Clinical observation of neonates with recurrent hypoglycemia.
• Biochemical testing to detect hyperinsulinism during hypoglycemic episodes.
• Genetic analysis to identify causative mutations and focal forms of CHI.
• Review of treatment protocols including dextrose, glucagon, diazoxide, and somatostatin analogues.

Main Results:

• Prompt recognition and treatment with dextrose and glucagon can mitigate hypoglycemia risks.
• Medical therapies like diazoxide and somatostatin analogues are effective when insulin is detectable.
• Genetic testing aids in understanding disease heterogeneity and guiding treatment escalation.
• Focal CHI amenable to surgery can be identified through genetic exploration.

Conclusions:

• Congenital hyperinsulinism requires vigilant pediatric attention for early diagnosis and intervention.
• A combination of biochemical, genetic, and clinical assessments informs management strategies.
• Specialized centers are essential for managing complex CHI cases and ensuring optimal long-term outcomes.